Have a
Question?
(+603) 7499 5911
Have a
Question?
Perceptron envisions becoming a global leader in fostering innovation within the life sciences sector by strategically investing in and advising early-stage companies with transformative potential.
The company aims to create a dynamic ecosystem that not only maximizes shareholder value but also contributes significantly to advancements in human health, agricultural productivity, and environmental sustainability, leveraging the integration of Digital Health and Artificial Intelligence.
Perceptron’s focus span a wide range of sectors, including biotechnology,
pharmaceuticals, medical devices, agricultural biotechnology, environmental
biotechnology, and more. The collaborations and partnerships built will
specialize in areas such as drug discovery and development, diagnostics, medical devices, genetic engineering, crop improvement, and bioinformatics, among others and enable access to global markets.
Generate revenue through advisory services, offering strategic guidance, operational optimization, and facilitating collaborations within the life sciences industry
Enhance the value of portfolio
companies by actively supporting their
growth, facilitating access to cutting edge technologies and harnessing
data
Explore opportunities to aggregate
and monetise valuable insights
derived from the data, contributing to
additional revenue streams
Leverage Digital and AI technologies
to extend patient reach, improve
diagnostics capabilities and enhance
effectiveness of portfolio companies
Al and machine learning are set to transform the life sciences sector, particularly
medical technology. The industry has yet to fully understand and exploit Al's
potential to drive new revenue and boost efficiency. At Perceptron we believe
health care services, life science tools and diagnostic and medical technology are
currently at the forefront of this innovation wave.
Perceptron has made a significant investment in OPUM, a company pioneering Al
and biomechanical solutions for orthopedic care and remote monitoring. OPUM's
focus is on addressing mobility issues and knee-related conditions, aiming to
improve quality of life and shape the future of orthopedic care. Some key points
regarding the investment in OPUM include:
OPUM is at the forefront of healthcare innovation with market-leading Al
technologies in orthopedic and remote monitoring. They have a patented, FDA-
listed clinical-grade knee sensor with unrivaled Al sensor technology. OPUM has
achieved regulatory clearances with favorable US reimbursement in place under
existing policies.
Key endorsements and clinical validations include a 29% reduction in intention to
undergo knee surgery and successful trials at the #1 US Rehab Hospital, proving
OPUM delays intervention and improves quality of life. They are in strategic
discussions with an established US brace manufacturer with the aim to sign a co-
marketing & distribution agreement in H1 2024.
OPUM has a significant addressable market in the United States, with knee
replacements expected to double by 2030. Their patent portfolio strategy
includes 7 patents filed for protection in major markets, covering 16 inventions
with 11 further inventions in the pipeline.
Overall, Perceptron's investment in OPUM appears to be well on its way, with the
company already at a commercial stage, having secured initial pilot and recurring
orders from ortho clinics in the US.
LS#1, a UK biotechnology company, has discovered immunomodulatory pregnancy-specific glycoproteins (PSGs) in the placenta, showing promise for treating immune-related medical conditions. These PSGs are safe and lack toxicity even under extreme conditions. They offer a new approach for diseases with dysregulated immune responses. The pharmaceutical industry is interested in placental immunomodulatory therapeutics, as PSGs play a role in maternal-fetal immune tolerance and could treat inflammatory disorders.
LS#1’s research extends beyond osteoarthritis (OA) to diseases like rheumatoid arthritis (RA), inflammatory bowel disease (IBD), autoimmune disorders, wound healing, and neuroinflammatory disorders. PSGs may help in RA by modulating inflammatory pathways, in IBD by reducing chronic inflammation, and in autoimmune disorders by managing aberrant immune responses. They also show promise in wound healing and neuroprotection for conditions like traumatic brain injury and neurodegenerative diseases.
LS#1 aims to develop a diverse range of PSG-based therapies to address inflammatory diseases, potentially improving patient outcomes and quality of life.
LS#2, a medical technology company, has developed Device X, a low-cost, rapid, and effective solution for benign
prostatic hyperplasia (BPH). Clinical studies show it provides symptom relief for up to 80% of sufferers, disrupting traditional treatments and capturing market share rapidly. With over 250 million global BPH sufferers, Device X has immense market potential.
Key points for partnership consideration include:
Market Disruption: Device X offers a convenient alternative to existing treatments, positioning LS#2 as a leader in BPH treatment.
Global Market Opportunity: Device X can address unmet medical needs worldwide.
Regulatory Approvals: CE Mark approval and FDA pre-sub program progress validate Device X’s efficacy and safety.
Continued Innovation: LS#2 is developing a Generation 2 device, ensuring it remains competitive.
Strong Intellectual Property: LS#2 has a robust patent portfolio protecting its technology.
Favorable Economics: Low production costs and high margins enhance LS#2’s profitability.
Experienced Management: LS#2’s team has extensive experience in the medical device industry, positioning the company for sustainable growth.
LS#2’s Device X presents a compelling investment opportunity with its innovative technology, market potential, regulatory progress, and experienced team.
The pre-clinical research industry faces a crisis of confidence due to data integrity issues and a lack of trust in research findings. Structural trends, such as increased regulatory scrutiny and pressure for animal welfare reforms, are reshaping the industry. This has led to wasted expenditure estimated at US$28 billion annually out of a total of US$38 billion. In response, Product X offers a comprehensive solution to enhance data reliability and reproducibility.
Product X’s ID Tattoo RFID Suite Solution revolutionizes mouse identification and tracking in pre-clinical research. It includes automated tattoo systems, high-quality consumables, RFID tags, insertion devices, readers, “Edge” computers, and cloud software. These features provide permanent and consistent mouse identification, are non invasive, and offer compatibility and scalability. By leveraging Product X’s solution, research organizations can improve data accuracy and reproducibility, leading to more reliable scientific discoveries.
LS#4 has developed a cloud-based solution for detecting diabetic retinopathy using eye fundus images and advanced machine learning algorithms. With over 537 million people affected by diabetes worldwide, diabetic retinopathy is a leading cause of blindness.
LS#4’s solution aims to provide accessible screening and treatment interventions, offering a cost-effective approach to early diagnosis.
The platform allows non medical staff to capture eye images in various settings, which are then uploaded for diagnosis. This approach improves accessibility to screening and streamlines the diagnostic process, reducing healthcare system burdens and improving patient outcomes. Investing in LS#4 is attractive due to its focus on addressing a critical health issue, substantial market potential, potential for impactful healthcare intervention, scalable business model, and technological advantage in Al-driven healthcare solutions.
LS#4’s innovative approach to diabetic retinopathy detection offers a compelling partnership opportunity, combining financial returns with the potential for significant social impact in improving healthcare outcomes.
Phytophthora and Fusarium Wilt are fungal diseases causing significant harm to agriculture and ecosystems globally. They affect around 60 crop varieties in over 100 countries, causing annual damages of $100 billion to $200 billion. These diseases also impact about 4,000 forestry species, affecting carbon sequestration and wildlife habitats.
A patented cure for Phytophthora and Fusarium Wilt has been developed by Australian scientists, showing efficacy in laboratory and field tests. This cure, now ready for commercialization, offers immense market potential by eradicating these diseases from commercial crops, improving yields, and enhancing food security. Additionally, its use in forestry could benefit carbon sequestration and wildlife habitat restoration efforts.
Radstone Capital Partners – unleashing the financial potential for high-net-worth visionaries.
Radstone Asia Berhad
B 1011, Phileo Damansara II, Pusat Perdagangan Phileo Damansara,
46350 Petaling Jaya, Selangor
T +603 7499 5911
E office@radstonecapital.com
Radstone Capital Partners Limited
Office Suite 1626. Level 16(A),
Main Office Tower, Financial
Park Complex, Jalan Merdeka,
Labuan, Federal Territory 87000,
Malaysia
T +608 758 4844
E office@radstonecapital.com
Interested in working with us?
office@radstonecapital.com
Are you the next big thing?
office@radstonecapital.com
